UK’s Covid-19 jab victims considered not ‘disabled enough’ – Telegraph
According to The Telegraph, thousands are pursuing compensation for injuries they claim were caused by Covid-19 vaccines. For further details, read the full article at RT.com.
TroibNews 
Nearly 14,000 individuals in the UK have filed for government compensation due to disabilities they attribute to Covid-19 vaccinations, The Telegraph reports.
Out of these applicants, only 175, representing less than 2% of the total, have received a one-time payment of £120,000 ($155,300), according to the newspaper's Saturday article.
The data revealed by The Telegraph, obtained through Freedom of Information requests, shows that approved claims predominantly came from recipients of the Oxford-AstraZeneca vaccine, with conditions reported including strokes, heart attacks, severe blood clots, spinal cord inflammation, significant swelling at the injection site, and facial paralysis. Approximately 97% of the approved claims were linked to the Oxford-AstraZeneca vaccine, while the remaining involved vaccines from Pfizer and Moderna.
Despite various European nations suspending the use of the AstraZeneca vaccine over blood clot concerns, the UK government maintained its recommendation for its use.
The Telegraph's article reveals that a significant number of claims were denied compensation, with government medical assessors citing a lack of definitive evidence linking the vaccines to the reported health issues. Additionally, many were rejected for not meeting the disability severity threshold; eligibility for the Vaccine Damage Payment Scheme (VDPS) requires at least 60% disability.
An AstraZeneca spokesperson stated to The Telegraph, "our vaccine has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects." Furthermore, on the matter of health issues linked to the vaccine, the spokesperson expressed, "our sympathy goes out to anyone who has lost loved ones or reported health problems."
In a recent development, AstraZeneca has started to phase out its vaccine globally, acknowledging that it can cause blood clots in rare instances, and citing newer vaccines tailored to current virus variants as more effective options.
Since the inception of the VDPS in 1979, about 16,000 individuals have applied for compensation, with the majority of claims coming from Covid-19 vaccine recipients. The processing capacity has been significantly expanded from four to 80 staff members within the last year to handle the increase in applications. "We continually review our processes to further develop the way in which we manage claims, and to provide a better service for claimants," noted a spokesperson from the National Health Service.
Camille Lefevre for TROIB News
Out of these applicants, only 175, representing less than 2% of the total, have received a one-time payment of £120,000 ($155,300), according to the newspaper's Saturday article.
The data revealed by The Telegraph, obtained through Freedom of Information requests, shows that approved claims predominantly came from recipients of the Oxford-AstraZeneca vaccine, with conditions reported including strokes, heart attacks, severe blood clots, spinal cord inflammation, significant swelling at the injection site, and facial paralysis. Approximately 97% of the approved claims were linked to the Oxford-AstraZeneca vaccine, while the remaining involved vaccines from Pfizer and Moderna.
Despite various European nations suspending the use of the AstraZeneca vaccine over blood clot concerns, the UK government maintained its recommendation for its use.
The Telegraph's article reveals that a significant number of claims were denied compensation, with government medical assessors citing a lack of definitive evidence linking the vaccines to the reported health issues. Additionally, many were rejected for not meeting the disability severity threshold; eligibility for the Vaccine Damage Payment Scheme (VDPS) requires at least 60% disability.
An AstraZeneca spokesperson stated to The Telegraph, "our vaccine has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects." Furthermore, on the matter of health issues linked to the vaccine, the spokesperson expressed, "our sympathy goes out to anyone who has lost loved ones or reported health problems."
In a recent development, AstraZeneca has started to phase out its vaccine globally, acknowledging that it can cause blood clots in rare instances, and citing newer vaccines tailored to current virus variants as more effective options.
Since the inception of the VDPS in 1979, about 16,000 individuals have applied for compensation, with the majority of claims coming from Covid-19 vaccine recipients. The processing capacity has been significantly expanded from four to 80 staff members within the last year to handle the increase in applications. "We continually review our processes to further develop the way in which we manage claims, and to provide a better service for claimants," noted a spokesperson from the National Health Service.
Camille Lefevre for TROIB News
